临床试验外包市场－全球产业规模、份额、趋势、机会及预测（依临床试验阶段、治疗领域、最终用户、地区及竞争格局划分，2021-2031年）

全球临床试验外包市场预计将从2025年的515.3亿美元成长到2031年的771.2亿美元，复合年增长率（CAGR）为6.95%。临床试验外包是指将研究任务（例如通讯协定设计、资料管理和现场监查）外包给外部供应商，以降低固定成本并提高营运柔软性。该市场的主要驱动力是製药研发公司，这些公司需要复杂治疗方法的专业知识，并负责管理全球整合研究的物流。根据临床研究组织协会（ACRO）统计，2024年，其成员公司参与或进行了8854项研究，涉及全球约170万名患者。

儘管市场持续扩张，但维持不同地区品管的一致性仍是限制市场成长的一大障碍。随着申办方将试验扩展到多个国家以确保患者群体的多样性，遵守不同的法规结构和严格的数据完整性标准的需求带来了显着的营运复杂性，并可能延长核准时间。

市场驱动因素

与药物研发相关的成本不断攀升，正促使企业转向外包，以此作为降低财务风险和维持研发管线永续性的策略性倡议。随着药物发现过程变得越来越依赖资本投入，申办方正将临床营运外包给外部供应商，有效地将固定基础设施成本转化为可控的可变支出。根据美国药品研究与製造商协会（PhRMA）于2024年8月发布的《2024年度会员调查报告》，预计会员公司在2023年将在研发领域投入总计1035亿美元，这凸显了巨大的财务负担，也促使企业转向受託研究机构（CRO）。这种模式使研发人员能够在应对现代药物研发高风险环境的同时，优化资源配置。

同时，中小型生物技术公司临床试验活动的激增正在显着改变外包格局。这些小规模的公司往往缺乏内部基础设施，严重依赖服务供应商来处理复杂的营运和监管合规事宜。根据摩根大通于2024年1月发布的《2024年生物製药许可创投年度报告》，2023年生物製药创投将达到231亿美元，这将为不断增长的研发管线提供支持，而这些研发管线需要外部支持。大量资金的涌入直接推动了对能够管理全球研发的专业供应商的需求，Icon Plc 2023年全年营收达81.2亿美元便印证了这一点。

市场挑战

确保跨区域的品管一致性和严格的监管合规性是全球临床试验外包市场的一大瓶颈。申办方正将试验范围扩展至全球，以涵盖不同的患者群体，但各地研究中心能力的差异造成了营运环境的碎片化。这种分散化迫使外包供应商投入大量资金用于纠正措施和额外监控，以维护资料完整性，从而直接降低了外包模式实施的速度和成本效益。区域差异导致供应商无法确保统一的合规性，延长了核准时间，并限制了市场扩充性。

这种营运上的不稳定性因研究中心层级的资源限製而进一步加剧，阻碍了复杂通讯协定的执行。根据临床研究中心协会 (SCRS) 发布的《2024 年研究中心环境调查报告》，超过 60% 的研究中心专业人员面临严重的员工短缺问题。合格人员的匮乏直接阻碍了满足各种法规结构所需的严格监测和资料管理。因此，由于资源匮乏地区监管合规的物流需求超过了全球部署带来的益处，市场难以维持成长势头。

市场趋势

机器学习 (ML) 和人工智慧 (AI) 的融合正在从根本上改变临床试验的进行方式，显着提升营运效率和预测分析能力。这一趋势已从理论概念发展到风险评估和患者识别等实际应用，使申办方能够分析大量资料集，从而精准优化通讯协定。借助这些演算法，外包供应商可以预测试验中心可能出现的问题，并显着缩短研发週期，以应对日益复杂的全球性研究。正如 2025 年 6 月《应用临床试验》杂誌发表的题为“人工智能解决方案影响的新见解”的报导中所述，塔夫茨药物研发研究中心 (CSDD) 的一项调查发现，35.2% 的申办方和合同研究组织 (CRO) 已在临床试验开展过程中部分或全部应用了人工智能/机器学习技术。

同时，混合型和分散式临床试验 (DCT) 模式的普及正在改变市场结构，减少对实体试验点的依赖。这种模式透过直接面向患者的物流和远端监测，满足了多样化患者招募和留存的关键需求。随着业界扩展这些混合工作流程，申办方正从试验计画转向企业级数位化策略，这就要求供应商提供整合平台，以确保在传统环境之外无缝收集数据。 Medable 在 2025 年 1 月发布的新闻稿《Medable 透过产品组合级电子临床结果评估 (eCOA) 部署实现 80% 的收入成长》中反映了这种日益增长的数位化依赖性，该新闻稿记录了 2024 年收入增长 80%，原因是申办方转向可扩展的产品组合级数位化试验投资。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球临床试验外包市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 临床试验阶段（0期、1期、2期、3期、4期）
  • 依治疗领域（肿瘤学、血液学、中枢神经系统、心血管及代谢、呼吸系统、传染病、感染疾病学、罕见疾病、医疗设备、其他）
  • 依最终用户划分（生物技术/製药公司、医疗设备公司、学术/研究机构）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美临床试验外包市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

7. 欧洲临床试验外包市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区临床试验外包市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲临床试验外包市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲临床试验外包市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章：全球临床试验外包市场：SWOT分析

第十四章 波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• ICON plc
• PAREXEL International Corp.
• Thermo Fisher Scientific, Inc
• Sygnature Discovery Limited
• WuXi AppTec Co., Ltd.
• Laboratory Corporation of America Holdings
• Jubilant Biosys Limited
• Charles River Laboratories International, Inc
• Albany Molecular Research, Inc
• Syneos Health Inc

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Clinical Trial Outsourcing Market is projected to expand from USD 51.53 Billion in 2025 to USD 77.12 Billion by 2031, registering a compound annual growth rate (CAGR) of 6.95%. Clinical trial outsourcing entails delegating research tasks, including protocol design, data management, and site monitoring, to external vendors to lower fixed costs and improve operational flexibility. This market is primarily fueled by pharmaceutical developers needing specialized expertise for complex therapies while managing the logistics of globalized studies. According to the Association of Clinical Research Organizations (ACRO), member companies participated in or conducted 8,854 studies involving roughly 1.7 million patients globally in 2024.

Despite this ongoing expansion, upholding consistent quality control across various geographic regions stands as a major obstacle to market growth. As sponsors increasingly spread trials across multiple countries to secure diverse patient enrollment, the necessity of strictly adhering to distinct regulatory frameworks and data integrity standards introduces significant operational complexity that can prolong approval timelines.

Market Driver

Rising costs associated with pharmaceutical R&D and drug development are compelling a strategic shift toward outsourcing to limit financial risks and sustain pipeline viability. As the drug discovery process becomes more capital-intensive, sponsors are delegating clinical operations to external vendors, effectively converting fixed infrastructure costs into manageable variable expenses. According to the '2024 PhRMA Annual Membership Survey' released by PhRMA in August 2024, member companies collectively invested $103.5 billion in R&D during 2023, a figure that highlights the substantial financial burden driving the transition to contract research organizations. This model enables developers to optimize resource allocation while navigating the high-stakes landscape of modern therapeutic development.

Concurrently, the increase in clinical trial activities by small and mid-sized biotech firms is significantly reshaping the outsourcing environment. These smaller entities, often lacking internal infrastructure, depend heavily on full-service providers to handle complex operational and regulatory tasks. J.P. Morgan's '2024 Annual Biopharma Licensing and Venture Report' from January 2024 indicates that biopharma venture investment hit $23.1 billion in 2023, supporting a strong pipeline of studies requiring external assistance. This capital influx directly drives demand for specialized vendors capable of managing global studies, as evidenced by Icon Plc recording full-year 2023 revenue of $8.12 billion in 2024.

Market Challenge

The difficulty of ensuring consistent quality control and strict regulatory adherence across diverse geographic regions serves as a critical bottleneck for the Global Clinical Trial Outsourcing Market. Although sponsors broaden trials globally to access diverse patient pools, variations in local site capabilities lead to a fragmented operational landscape. This fragmentation compels outsourcing vendors to invest heavily in remediation and additional oversight to maintain data integrity, which directly diminishes the speed and cost-efficiency that drive the outsourcing model. When vendors cannot ensure uniform compliance due to regional disparities, approval timelines extend, and market scalability is restricted.

This operational instability is further aggravated by resource constraints at the site level, which hinder the execution of complex protocols. The Society for Clinical Research Sites (SCRS) reported in its 2024 Site Landscape Survey that over 60% of site professionals face significant staffing shortages. This scarcity of qualified personnel directly impedes the rigorous monitoring and data management necessary to navigate varying regulatory frameworks. Consequently, the market struggles to maintain growth momentum as the logistical demands of ensuring regulatory compliance in under-resourced regions outweigh the advantages of global reach.

Market Trends

The integration of Machine Learning (ML) and Artificial Intelligence (AI) is fundamentally transforming clinical trial execution by improving operational efficiency and predictive analytics. This trend has advanced from theoretical concepts to practical application in risk assessment and patient identification, enabling sponsors to analyze massive datasets for accurate protocol optimization. By utilizing these algorithms, outsourcing vendors can forecast site performance issues and significantly shorten development timelines to address the rising complexity of global studies. As noted in the article 'New Insights On the Impact of AI-Enabled Solutions' by Applied Clinical Trials in June 2025, a survey by the Tufts Center for the Study of Drug Development (CSDD) revealed that 35.2% of sponsor companies and CROs have partially or fully adopted AI/ML activities related to clinical trial execution.

Simultaneously, the widespread acceptance of Hybrid and Decentralized Clinical Trial (DCT) models is reshaping the market by reducing reliance on physical sites. This model meets critical needs for diverse enrollment and patient retention through direct-to-patient logistics and remote monitoring. As the industry scales these hybrid workflows, sponsors are shifting from pilot programs to enterprise-wide digital strategies, requiring vendors to offer integrated platforms that ensure seamless data capture outside traditional settings. This increase in digital reliance is reflected in Medable's January 2025 press release, 'Medable Reports 80% Revenue Growth from Portfolio-Level eCOA Adoption', which recorded an 80% revenue increase for 2024 driven by sponsors moving toward scalable, portfolio-level digital trial investments.

Key Market Players

• ICON plc
• PAREXEL International Corp.
• Thermo Fisher Scientific, Inc
• Sygnature Discovery Limited
• WuXi AppTec Co., Ltd.
• Laboratory Corporation of America Holdings
• Jubilant Biosys Limited
• Charles River Laboratories International, Inc
• Albany Molecular Research, Inc
• Syneos Health Inc

Report Scope

In this report, the Global Clinical Trial Outsourcing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Clinical Trial Outsourcing Market, By Clinical Trial Phase

• Phase 0
• Phase 1
• Phase 2
• Phase 3
• Phase 4

Clinical Trial Outsourcing Market, By Therapeutic Area

• Oncology
• Hematology
• Central Nervous System
• Cardiovascular/Metabolic
• Respiratory
• Infectious Diseases
• Immunology
• Rare Diseases
• Medical Devices
• Others

Clinical Trial Outsourcing Market, By End User

• Biotechnology & Pharmaceutical Companies
• Medical Device Companies
• Academic & Research Institutions

Clinical Trial Outsourcing Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Clinical Trial Outsourcing Market.

Available Customizations:

Global Clinical Trial Outsourcing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Clinical Trial Outsourcing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Clinical Trial Phase (Phase 0, Phase 1, Phase 2, Phase 3, Phase 4)
  • 5.2.2. By Therapeutic Area (Oncology, Hematology, Central Nervous System, Cardiovascular/Metabolic, Respiratory, Infectious Diseases, Immunology, Rare Diseases, Medical Devices, Others)
  • 5.2.3. By End User (Biotechnology & Pharmaceutical Companies, Medical Device Companies, Academic & Research Institutions)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Clinical Trial Outsourcing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Clinical Trial Phase
  • 6.2.2. By Therapeutic Area
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Clinical Trial Outsourcing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Clinical Trial Phase
      • 6.3.1.2.2. By Therapeutic Area
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Clinical Trial Outsourcing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Clinical Trial Phase
      • 6.3.2.2.2. By Therapeutic Area
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Clinical Trial Outsourcing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Clinical Trial Phase
      • 6.3.3.2.2. By Therapeutic Area
      • 6.3.3.2.3. By End User

7. Europe Clinical Trial Outsourcing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Clinical Trial Phase
  • 7.2.2. By Therapeutic Area
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Clinical Trial Outsourcing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Clinical Trial Phase
      • 7.3.1.2.2. By Therapeutic Area
      • 7.3.1.2.3. By End User
  • 7.3.2. France Clinical Trial Outsourcing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Clinical Trial Phase
      • 7.3.2.2.2. By Therapeutic Area
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Clinical Trial Outsourcing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Clinical Trial Phase
      • 7.3.3.2.2. By Therapeutic Area
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Clinical Trial Outsourcing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Clinical Trial Phase
      • 7.3.4.2.2. By Therapeutic Area
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Clinical Trial Outsourcing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Clinical Trial Phase
      • 7.3.5.2.2. By Therapeutic Area
      • 7.3.5.2.3. By End User

8. Asia Pacific Clinical Trial Outsourcing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Clinical Trial Phase
  • 8.2.2. By Therapeutic Area
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Clinical Trial Outsourcing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Clinical Trial Phase
      • 8.3.1.2.2. By Therapeutic Area
      • 8.3.1.2.3. By End User
  • 8.3.2. India Clinical Trial Outsourcing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Clinical Trial Phase
      • 8.3.2.2.2. By Therapeutic Area
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Clinical Trial Outsourcing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Clinical Trial Phase
      • 8.3.3.2.2. By Therapeutic Area
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Clinical Trial Outsourcing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Clinical Trial Phase
      • 8.3.4.2.2. By Therapeutic Area
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Clinical Trial Outsourcing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Clinical Trial Phase
      • 8.3.5.2.2. By Therapeutic Area
      • 8.3.5.2.3. By End User

9. Middle East & Africa Clinical Trial Outsourcing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Clinical Trial Phase
  • 9.2.2. By Therapeutic Area
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Clinical Trial Outsourcing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Clinical Trial Phase
      • 9.3.1.2.2. By Therapeutic Area
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Clinical Trial Outsourcing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Clinical Trial Phase
      • 9.3.2.2.2. By Therapeutic Area
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Clinical Trial Outsourcing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Clinical Trial Phase
      • 9.3.3.2.2. By Therapeutic Area
      • 9.3.3.2.3. By End User

10. South America Clinical Trial Outsourcing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Clinical Trial Phase
  • 10.2.2. By Therapeutic Area
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Clinical Trial Outsourcing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Clinical Trial Phase
      • 10.3.1.2.2. By Therapeutic Area
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Clinical Trial Outsourcing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Clinical Trial Phase
      • 10.3.2.2.2. By Therapeutic Area
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Clinical Trial Outsourcing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Clinical Trial Phase
      • 10.3.3.2.2. By Therapeutic Area
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Clinical Trial Outsourcing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. ICON plc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. PAREXEL International Corp.
• 15.3. Thermo Fisher Scientific, Inc
• 15.4. Sygnature Discovery Limited
• 15.5. WuXi AppTec Co., Ltd.
• 15.6. Laboratory Corporation of America Holdings
• 15.7. Jubilant Biosys Limited
• 15.8. Charles River Laboratories International, Inc
• 15.9. Albany Molecular Research, Inc
• 15.10. Syneos Health Inc

16. Strategic Recommendations

17. About Us & Disclaimer